Odrc Enterprises LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$433,434	81
2024	Research	$518,761	79
2023	Research	$92,110	27
2022	Research	$47,550	22
2021	Research	$77,803	8

Breakdown

Who paid Research payments · program years 2021–2025

AbbVie, Inc. $953,838 169 payments
Pfizer Inc. $189,802 32 payments
Sun Pharmaceutical Industries Inc. $16,114 6 payments
Galderma Laboratories, L.P. $9,571 9 payments
Dermavant Sciences, Inc. $332 1 payment

Studies the money was for Research payments · program years 2021–2025

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $230,389 28 payments
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $164,820 21 payments
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $119,190 25 payments
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis $103,091 9 payments
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $102,475 15 payments
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $89,439 16 payments
A Phase 2A Randomized Double Blind Vehicle Controlled Parallel Group Study to Assess the Efficacy Safety Tolerability and Pharmacokinetics of Pf07038124 Ointment for 6 Weeks in Participants With Mild to Moderate Atopic Dermatitis Or Plaque Psoriasis $70,612 7 payments
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $50,861 31 payments
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) $28,151 11 payments
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $23,172 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.